Sareum Holdings — Sareum Holdings – executive interview

In this video, executive chairman Dr Stephen Parker and chief scientific officer Dr John Reader outline the strategic rationale for this expansion and Sareum’s new collaboration with Receptor.AI to identify novel, brain-penetrating TYK2 compounds. Management highlighted the potential of TYK2/JAK1 inhibition in neuroinflammation and the technical challenge of designing brain-penetrant kinase inhibitors that can cross the blood–brain barrier while maintaining isoform selectivity and optimal local bioavailability. They also discuss the competitive landscape and commercial potential for JAK inhibitors in central nervous system. The interview concludes with a recap of expected development milestones and catalysts over the next 12–18 months.

Sareum Holdings (AIM: SAR) is a UK-listed biopharma focused on the development of small-molecule kinase inhibitors. Best known for its next-generation TYK2/JAK1 inhibitors in autoimmune and oncology indications (with SDC-1801 and SDC-1802, respectively), the company has recently expanded its efforts into targeting the central nervous system, driven by the growing interest in TYK2 as a compelling target in neuroinflammatory conditions.